ABSTRACT
Aim To express and purify rhα-Gal A with a 6 X His tag via using a serum-free expression system in high-density suspension culture of Chinese hamster ovary cells ( CHO-S) , and to verify the scavenging effect of rhα-Gal A on globular trisaccharide ceramide (Gb3 or GL3) . Methods The construction of recombinant protein expression vector, pcDNA4-GLA, was achieved by fusing the human α-galactosidase cDNA, gla, with 6 X His tag and artificial DNA synthesis. The expression plasmid was transfected into the suspended CHO-S to express rhα-Gal A and then purified. Following this procedure, we determined rhα-Gal A's expression, the enzymatic activity, and the glycosylation of the recombinant enzyme. Co-incubation with cultured cells was performed to examine whether rhα-Gal A could be taken up into the cells and effectively remove Gb3 substrates. Results rhα-Gal A was successfully expressed and purified after transiently transfecting pcDNA4-GLA into the suspended CHO-S, and the yield was up to (100 ±20. 6) mg • L
ABSTRACT
Objective: To evaluate the efficacy and safety of qiliqiangxin capsule in treating the patients with chronic heart failure (CHF). Methods: We searched the databases of Pubmed, EMBASE, Web of science, Wanfang, VIP, CBM and CNKI from 2007-01 to 2017-03 to collect the randomized trials of qiliqiangxin capsule in treating CHF patients. Blood levels of NT-proBNP, 6 minutes walkingdistance (6MWD), left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDD) and Minnesota living with heart failure questionnaire (MLHFQ) scores were compared between qiliqiangxin capsule treated patients and control patients. Results: A total of 22 randomized trials were finally enrolled which included 1988 patients by 2 groups: Qiliqiangxin capsule group, n=1002 and Control group, n=986. Patients were followed-up at the mean 6.5 months. Compared with Control group, Qiliqiangxin capsule group had decreased blood level of NT-proBNP, weighted mean difference (WMD)= -194.97, 95％ CI (-287.95 to -101.99), increased LVEF, WMD=5.24, 95％ CI (3.38-7.11), reduced LVEDD, WMD= -0.94, 95％ CI (-1.46 to -0.43), elevated 6MWD, WMD=53.81, 95％ CI (46.9-60.73), lower MLHFQ score WMD= -8.11, 95％ CI(-10.23 to -6.0) and less adverse events occurrence, OR=0.44, 95％ CI (0.25-0.79),P<0.01. Conclusion: Qiliqiangxin capsule was safe and effective for improving the cardiac function and quality of life in CHF patients.
ABSTRACT
Objective: To observe the clinical efficacy and adverse reactions of chemotherapy with oxaliplatin in combination with either S-1 or paclitaxel liposome as the first-line therapy for advanced gastric cancer. Methods: Ninety-two patients with advanced gastric carcinoma were divided into two groups. In group A (46 cases), oxaliplatin combined with S-1 were administered. In group B (46 cases), oxaliplatin combined with paclitaxel liposome were administered. The shortterm curative effect, progression-free survival (PFS), overall survival (OS) and adverse reactions were observed and compared between the two groups. Results: There were no significant differences in the objective response rate, disease control rate and median PFS between group A and group B (41.3% vs 45.7%, 73.9% vs 71.7%, 5.3 months vs 4.6 months; all P > 0.05). The median OS in group A and group B were 12.2 and 10.2 months, respectively, with a statistically significant difference (P < 0.05). The joint and muscle pain and neutropenia in group B were more severe than those in group A (P < 0.05). Conclusion: These two chemotherapy regimens have the similar clinical efficacy for advanced gastric cancer, but oxaliplatin combined with S-1 could be superior to oxaliplatin plus paclitaxel liposome in OS and tolerance of chemotherapeutic toxicities.
ABSTRACT
<p><b>OBJECTIVE</b>To examine the influence of chemotherapy with FOLFOX protocol (CT-F) on the immunologic function in patients with advanced colorectal cancer.</p><p><b>METHODS</b>A total of 43 patients with advanced colorectal cancer were included. Patients who received FOLFOX chemotherapy (Group A, n=22) were compared to those who did not(Group B, n=21). Blood was obtained from peripheral vein before chemotherapy (T0), at the time of completion of chemotherapy (T1), and 3 months after completion of chemotherapy (T2) to detect the percentage of regulatory T lymphocytes (CD4+CD25+Foxp3+T cells) in total T lymphocytes using fluorescence activated cell sorter (FACS). The level of Th1/Th2 cytokines in the serum including interleukin-2 (IL-2), interleukin-4 (IL-4), interleukin-10 (IL-10) and interferon-γ (IFN-γ) were detected by enzyme-linked immunoabsorbent assay(ELISA).</p><p><b>RESULTS</b>The percentage of regulative T lymphocyte was significantly lower at T1, which increased after chemotherapy but was still lower than that at T0 and that in Group B [(4.15±0.56)%, (5.60±0.88)%, and(5.38±0.92)%, all P<0.01]. The levels of IL-4, IL-10 decreased at T1, and increased to the normal level at T2 compared with those at T0 or those in the control group (all P<0.01). In contrast, the levels of IL-2 and IFN-γ increased significantly at T1 and decreased to the normal level at T2 during the entire observation period.</p><p><b>CONCLUSION</b>For patients with advanced colorectal cancer, FOLFOX chemotherapy can decrease the proportion of regulatory T lymphocytes and results in Th1/Th2 cytokine drift to Th1 type. Therefore, FOLFOX may help the release from the anticancer immune inhibition.</p>